In association with
About the organisation:
MedImmune was established in 2007 as the global biologics business for AstraZeneca, and has one of the most robust pipelines in the biopharmaceutical industry.
Why you should attend:
- Learn about history of studies in COPD subjects have used pulmonary function (FEV1) as end-point
- Analyse current trends that focus on reducing acute exacerbations and or improvements of quality of life
- Discuss new end-points, if validated or if clinically meaningful that are being considered
- Focus on new end-points and study designs in COPD to establish Proof of Concept in drug development
Where does the event take place?
This Workshop will take place in central London, UK
|
What is this event about?
The workshop will evaluate past proof of concept trials in COPD, their pitfalls & leanings. An overview of challenge models will be discussed as means to provide a faster proof of concept trial in COPD. The case study will allow teams to design a clinical trial to obtain confidence in moving forward with product development. Teams will each discuss the study design that will best suite the mechanism of action of the drug.
Who is leading this event?
René van der Merwe, Director - Clinical Development, Respiratory and Inflammation, MedImmune.
Rene van der Merwe is South African trained physician who has held various positions in the pharmaceutical industry including leading the medical department and being Principal Investigator at a Phase I CRO, at the time an affiliate of Serono and Director roles in GlaxoSAE Media GroupthKline in Neurosciences and Auto-inflammation.
Her current position is Director of Clinical Development Respiratory and Auto-inflammation at MedImmune, the biologics arm of Astra Zeneca.
|
|
Who should attend this event?
Industry professionals in positions such as:
- Chief Medical Officer
- Chief Scientist
- Clinical Pharmacologist
- Senior Medical Adviser
- Managing Director
- Director of Medical Affairs
- Clinical Trial Project Manager
- Principal Scientist
- R&D Project Leader
- Head of Respiratory Pharmacology
- Managing Director
|